+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Current treatment indications and strategies in chronic hepatitis B virus infection



Current treatment indications and strategies in chronic hepatitis B virus infection



World Journal of Gastroenterology 14(45): 6902-6910



The optimal approach to the management of several marginal cases with chronic hepatitis B virus (HBV) infection is controversial. Serum HBV DNA and aminotransferase levels, and the degree of necroinflammation and fibrosis determine the therapeutic decisions. All patients with elevated aminotransferase (>twice the upper limit of normal) and serum HBV DNA above 20000 IU/mL should be treated. Liver biopsy is important for therapeutic decisions in cases with mild aminotransferase elevations and serum HBV DNA below 20000 IU/mL. Chronic HBV patients who do not receive treatment should be followed for life. There are seven agents licensed for chronic hepatitis B: standard and pegylated interferon-alpha, lamivudine, adefovir, entecavir, telbivudine and tenofovir. One-year courses with pegylated interferon-alpha induce sustained off-therapy remission in 30%-32% of patients with HBeAg-positive chronic hepatitis B and in a smaller proportion of patients with HBeAg-negative chronic hepatitis B. Oral antivirals achieve initial on-therapy responses in the majority of patients, but are intended as long-term therapies. Viral suppression has favourable effects on patients' outcome and modifies the natural course of the disease. Viral resistance, however, is the major drawback of long-term oral antiviral therapy. Lamivudine monotherapy is associated with the highest and entecavir monotherapy with the lowest resistance rate so far. There has been no resistance to tenofovir, but after only 18 mo of treatment to date. The optimal first-line anti-HBV therapy with the best long-term cost/benefit ratio remains unclear. If oral antiviral agents are used, compliance should always be ascertained and HBV DNA levels should be regularly tested.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 052414557

Download citation: RISBibTeXText

PMID: 19058323


Related references

Chronic Hepatitis C Virus Infection: A Review of Current Direct-Acting Antiviral Treatment Strategies. North American Journal of Medicine & Science 9(2): 47-54, 2016

Indications and efficacy of hepatitis B vaccines (HB vaccines) and hepatitis B immune globulin (HBIG): current situations and problems of hepatitis B virus (HBV) infection-preventing strategies in Japan. Nihon Rinsho. Japanese Journal of Clinical Medicine 69 Suppl 4: 408-416, 2011

Current drug discovery strategies for treatment of hepatitis C virus infection. Journal of Pharmacy and Pharmacology 63(7): 883-892, 2011

Strategies for treatment of chronic hepatitis B virus infection. Zhonghua Gan Zang Bing Za Zhi 14(11): 801-802, 2006

Treatment strategies for chronic hepatitis C virus infection. Journal of Gastroenterology 35(6): 411-423, 2000

Chronic hepatitis B virus infection: treatment strategies for the next millennium. Annals of Internal Medicine 132(9): 723-731, 2000

Current status of treatment for chronic hepatitis C virus infection. Drugs of Today 48(3): 219-231, 2012

The current state and future prospects of chronic hepatitis C virus infection treatment. Current Infectious Disease Reports 16(8): 413-413, 2014

Antiviral strategies in chronic hepatitis B virus infection: I. Establishment of an in vitro system using the duck hepatitis B virus model. Journal of Medical Virology 31(2): 82-89, 1990

Antiviral strategies in chronic hepatitis b virus infection inhibition of duck hepatitis b virus replication in vitro by pyrimidine analogs. Antiviral Research 17(SUPPL 1): 146, 1992

Prevalence and significance of hepatitis GB virus-C/hepatitis G virus viremia in a large cohort of patients with chronic hepatitis B infection, with chronic hepatitis C infection, and on renal replacement therapy in Hong Kong. Digestive Diseases & Sciences 47(2): 432-437, February, 2002

Current indications for triple therapy in hepatitis C virus infection. Gastroenterologia Y Hepatologia 35(4): 266-277, 2012

Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans. Hepatology 31(5): 1165-1175, 2000